Zulresso is an IV injection used to treat the sometimes life-threatening condition of postpartum depression, which is a major depressive episode that occurs following or leading up to childbirth.
Post Top Ad
Wednesday, March 20, 2019
Home
CNBC
Top News & Analysis
Sage Therapeutics stock rises after FDA approves first postpartum depression drug Zulresso
Sage Therapeutics stock rises after FDA approves first postpartum depression drug Zulresso
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment